Natco Pharma Raises Investment in US Biotech Firm eGenesis to $16.7 Million
Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis Inc to USD 16.7 million from the earlier USD 14 million, raising its total investment to USD 24.7 million. The investment, made through Natco's Canadian and US subsidiaries, involves purchasing convertible promissory notes with an 8% annual interest rate. eGenesis focuses on gene-editing technologies for organ transplantation, including recent pig kidney transplants into humans under FDA approval, aiming to address organ shortages and unmet medical needs.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 44/100.
Outlets measured: moneycontrol, businessstandard, news18, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 28 Sept, 01:31 pm. Other outlets followed.